Nyrada (ASX:NYR) Inc CEO James Bonnar joins Proactive’s Jonathan Jackson to highlight important developments for the company during the last quarter. He outlines how its lead drug candidate, NYR-BI03, has shown promising results during preclinical studies. This sets the stage for first-in-human Phase I clinical trials slated for the second quarter of FY2025. Nyrada has also kick-started Good Laboratory Practice (GLP) safety studies, with completion expected in the first half of FY2025, laying the groundwork for these crucial clinical trials. The company's financial health is robust, boasting a cash position of A$5.6 million, thanks to a fully subscribed placement raising A$1.76 million. Additionally, Nyrada is collaborating with the Walter Reed Army Institute of Research to commence a Traumatic Brain Injury Study in the fourth quarter of FY2024. Finally, Bonnar looks at the progress being made in continued efforts with a Cholesterol Lowering Program as the company remains at the forefront of innovative medical research, poised for significant breakthroughs. Stay tuned as we track Nyrada's journey through these pivotal developments in its quest to combat brain injuries and cholesterol-related health issues.
Nyrada delivers promising preclinical stroke study results
